Rigel Pharmaceuticals (RIGL) Net Cash Flow (2010 - 2026)

Rigel Pharmaceuticals' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$16.2 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 47.51% year-over-year to -$16.2 million; the TTM figure through Mar 2026 stood at -$21.3 million (down 205.47% YoY), while the FY2025 annual figure was -$16.1 million, down 167.23% from the prior year.
• Net Cash Flow was -$16.2 million for Q1 2026 at Rigel Pharmaceuticals, down from -$8.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $15.8 million in Q1 2023 to a low of -$16.2 million in Q1 2026.
• Historically, Net Cash Flow has averaged $328117.6 across 5 years, with a median of $2.5 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow jumped 560.24% in 2024, then plunged 257.38% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$5.4 million in 2022, then tumbled by 133.55% to -$12.6 million in 2023, then surged by 140.02% to $5.1 million in 2024, then slumped by 257.38% to -$8.0 million in 2025, then tumbled by 103.28% to -$16.2 million in 2026.
• The last three Net Cash Flow figures came in at -$16.2 million (Q1 2026), -$8.0 million (Q4 2025), and -$4.9 million (Q3 2025), per Business Quant data.